Spots Global Cancer Trial Database for bone marrow aspirate
Every month we try and update this database with for bone marrow aspirate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | NCT06013423 | Acute Leukemia ... Acute Lymphobla... Acute Myeloid L... Blastic Plasmac... Hematopoietic a... Mixed Phenotype... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Chronic Myeloid... | Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Cyclosporine Diagnostic Imag... Echocardiograph... Fludarabine Pho... Multigated Acqu... Mycophenolate M... Survey Administ... Thiotepa Total-Body Irra... Umbilical Cord ... | 6 Months - 65 Years | Fred Hutchinson Cancer Center | |
| A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. | NCT02663752 | Myelodysplastic... | Bone marrow asp... Deferasirox | 18 Years - | Novartis | |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | NCT03399773 | Acute Biphenoty... Acute Lymphobla... Chronic Myeloge... Hematopoietic a... Myelodysplastic... Myelodysplastic... | Dilanubicel Cyclophosphamid... Fludarabine Thiotepa Total-Body Irra... Umbilical Cord ... Laboratory Biom... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Multigated Acqu... Electrocardiogr... Computed Tomogr... | 10 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma | NCT04341740 | Renal Cell Carc... Urothelial Carc... | Bone Marrow Asp... | 18 Years - | University of Oklahoma | |
| Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma | NCT05847569 | Recurrent Multi... Refractory Mult... | Belantamab Mafo... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Magnetic Resona... Positron Emissi... | 18 Years - | Mayo Clinic | |
| Nature Sights and Sounds to Reduce Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy | NCT00315796 | Cancer | Biophilic Natur... | 18 Years - | Johns Hopkins University | |
| Nature Sights and Sounds to Reduce Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy | NCT00315796 | Cancer | Biophilic Natur... | 18 Years - | Johns Hopkins University | |
| Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 | NCT02320656 | Acute Leukemia Myelodysplastic... Myeloproliferat... | Blood sampling Bone marrow asp... Skin biopsy Buccal swab | 18 Years - | Institut Paoli-Calmettes | |
| Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma | NCT04341740 | Renal Cell Carc... Urothelial Carc... | Bone Marrow Asp... | 18 Years - | University of Oklahoma | |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | NCT05554393 | Acute Myeloid L... | Azacitidine Biospecimen Col... Bone Marrow Asp... Cytarabine Daunorubicin Hy... Venetoclax | 18 Years - 59 Years | National Cancer Institute (NCI) | |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | NCT03660826 | Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | NCT04870944 | Diffuse Midline... Metastatic Mali... Recurrent Diffu... Recurrent Lymph... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Oste... Refractory Prim... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... FACT Complex-ta... | 12 Months - 30 Years | Children's Oncology Group | |
| MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | NCT03285607 | Breast Cancer Cancer of Breas... | MCS110 Doxorubicin Cyclophosphamid... Paclitaxel Bone marrow asp... Peripheral bloo... Tumor tissue | 18 Years - | Washington University School of Medicine | |
| Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy | NCT06279572 | Acute Myeloid L... | Biospecimen Col... Bone Marrow Asp... Electronic Heal... | 18 Years - | Mayo Clinic | |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | NCT03660826 | Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | NCT03941860 | Multiple Myelom... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ixazomib Citrat... Lenalidomide Placebo Adminis... Positron Emissi... Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | NCT04870944 | Diffuse Midline... Metastatic Mali... Recurrent Diffu... Recurrent Lymph... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Oste... Refractory Prim... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... FACT Complex-ta... | 12 Months - 30 Years | Children's Oncology Group | |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | NCT05554393 | Acute Myeloid L... | Azacitidine Biospecimen Col... Bone Marrow Asp... Cytarabine Daunorubicin Hy... Venetoclax | 18 Years - 59 Years | National Cancer Institute (NCI) | |
| Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy | NCT06279572 | Acute Myeloid L... | Biospecimen Col... Bone Marrow Asp... Electronic Heal... | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
